Financial Data and Key Metrics Changes - For Q4 2025, organic sales growth was 11%, and for the full year, it was 10.3%, surpassing $25 billion in sales [4][12] - Full-year U.S. organic sales growth was 11.2%, while international organic sales growth was 7.5% [4] - Adjusted earnings per share for Q4 was $4.47, up 11.5% year-over-year, and for the full year, it was $13.63, up 11.8% [14][12] - Adjusted gross margin was 65.2%, and adjusted operating margin was 30.2%, reflecting operational improvements [19][12] Business Line Data and Key Metrics Changes - MedSurg and Neurotechnology had organic sales growth of 12.6%, with U.S. growth of 13% and international growth of 10.9% [15] - Instruments achieved U.S. organic sales growth of 19.1%, driven by strong demand in power tools and surgical technologies [15] - Endoscopy had U.S. organic sales growth of 11.1%, led by strong performances in Sustainability and Sports Medicine [15] - Vascular reported U.S. organic sales growth of 4.3%, with strong performance in the hemorrhagic business offset by competitive pressures in the ischemic sector [16] Market Data and Key Metrics Changes - International results were bolstered by strong performances in emerging markets, particularly South Korea and Japan [6] - The U.S. capital-related businesses showed robust performance, contributing to double-digit organic sales growth [9] - Hospital CapEx budgets remain healthy, and the capital order book is elevated as the company enters 2026 [9] Company Strategy and Development Direction - The company is focused on maintaining high growth through exceptional talent, active M&A, and systematic specialization [7] - The introduction of new business units, such as SmartCare, and splitting sales forces has contributed to growth [7] - The company expects to continue delivering growth at the high end of MedTech, with a strong financial position to support M&A activities in 2026 [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of procedural volumes and market conditions for 2026, driven by robotic-assisted surgery and favorable demographics [9] - The company anticipates organic net sales growth for 2026 to be in the range of 8%-9.5% and adjusted net earnings per share between $14.90-$15.10 [21][22] - Management remains optimistic about the potential for continued growth despite tariff impacts and competitive pressures [22] Other Important Information - The company expects full-year tariff impacts to be approximately $400 million in 2026, with an incremental $200 million compared to 2025 [22] - Cash from operations for the year was $5 billion, an increase of $802 million from 2024, indicating strong cash flow performance [21] Q&A Session Summary Question: Confidence in 2026 organic growth guidance - Management expressed confidence due to a strong order book and robust Mako performance, suggesting a potential for 10% growth depending on macro conditions [25][26] Question: Impact of leadership changes - The elevation of Spencer Stiles to president and COO is seen as a strategic move to enhance leadership and operational focus, allowing the CEO to concentrate on broader strategic initiatives [29] Question: Pricing expectations for capital and implant businesses - Management expects pricing to remain stable in 2026, with a focus on maintaining price gains achieved in previous years [32] Question: Performance of Trauma and Extremities and Vascular businesses - Management acknowledged strong prior year comparisons affecting Trauma and Extremities, while the Vascular business faced challenges in the ischemic sector but remains strong in hemorrhagic [36][38] Question: Competitive landscape changes - Management indicated no change in strategy despite competitors' moves, expressing confidence in their market position and capabilities [41] Question: Patient volume concerns related to healthcare policy changes - Management noted robust volumes as they entered 2026, with expectations for continued growth in orthopedic markets [43] Question: Recurring revenue model - Approximately 75% of revenue is procedurally driven, with a significant portion tied to recurring and disposables [82]

Financial Data and Key Metrics Changes - For Q4 2025, organic sales growth was 11%, and for the full year, it was 10.3%, surpassing $25 billion in sales [3][11] - Adjusted earnings per share for Q4 was $4.47, up 11.5% year-over-year, while full-year adjusted earnings per share was $13.63, up 11.8% from 2024 [12][19] - Adjusted operating margin was 30.2% for Q4, an increase of 100 basis points compared to Q4 2024 [18] Business Line Data and Key Metrics Changes - MedSurg and Neurotechnology achieved organic sales growth of 12.6% in Q4, with U.S. growth at 13% and international growth at 10.9% [13] - Instruments had U.S. organic sales growth of 19.1%, driven by strong demand in power tools and surgical technologies [13] - Vascular experienced U.S. organic sales growth of 4.3%, with strong performance in the hemorrhagic business offset by competitive pressures in the ischemic sector [14] Market Data and Key Metrics Changes - U.S. organic sales growth was 11.2%, while international organic sales growth was 7.5%, with strong performances in emerging markets like South Korea and Japan [3][4] - The capital environment remains healthy, with robust hospital CapEx budgets and an elevated capital order book entering 2026 [7][30] Company Strategy and Development Direction - The company is focused on maintaining high growth through exceptional talent, active M&A, and systematic specialization by creating new business units [5] - The new SmartCare business unit combines Vocera and CareAI, reflecting the company's strategy to innovate and expand its product offerings [5] - The company expects to continue delivering growth at the high end of medtech, with guidance for 2026 organic net sales growth in the range of 8%-9.5% [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of procedural volumes and the capital environment for 2026, driven by the adoption of robotic-assisted surgery and favorable demographics [7][30] - The company anticipates a slight positive impact from pricing and foreign exchange rates in 2026, with expected tariff impacts of approximately $400 million [20] Other Important Information - Cash from operations for the year was $5 billion, an increase of $802 million from 2024, resulting in free cash flow as a percentage of adjusted net earnings of 81% [19] - The company is set to launch several new products in 2026, including the Mako RPS handheld robot and the Incompass Total Ankle [58][60] Q&A Session Summary Question: Confidence in 2026 organic growth guidance - Management indicated that the strong order book and Mako performance give them confidence to start 2026 with a higher growth range than the previous year, with 10% growth still possible depending on macro conditions [22][23] Question: Impact of leadership changes - The elevation of Spencer Stiles to president and COO is seen as a strategic move to enhance leadership and operational focus, allowing the CEO to concentrate on broader strategic initiatives [25][26] Question: Pricing expectations for 2026 - Management expects pricing to remain stable in 2026, building on previous gains, with a favorable capital environment supporting this outlook [28][30] Question: Performance of specific business lines - Management acknowledged strong performances in Endoscopy and Instruments, while noting challenges in Trauma and Extremities due to tough comparisons from the previous year [32][34] Question: Competitive landscape changes - Management stated that their strategy remains unchanged despite competitors' moves, emphasizing confidence in their market position and product offerings [38][39] Question: Patient volume concerns - Management reported robust patient volumes as they enter 2026, with expectations for mid-single-digit growth in ortho markets [41] Question: Recurring revenue model - Approximately 75% of revenue is procedurally driven, with a significant portion tied to recurring and disposable products [86] Question: Future innovation and product launches - Management highlighted ongoing innovation, including the Mako RPS and other new products, as key drivers for future growth [58][60]

Group 1 - The company expects a significant increase in net profit for the year 2025, projecting a range of CNY 244.99 million to CNY 287.99 million, which represents an increase of CNY 120 million to CNY 163 million compared to the previous year, translating to a year-on-year growth of 96.01% to 130.41% [3] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is estimated to be between CNY 229.54 million and CNY 269.54 million, indicating an increase of CNY 135 million to CNY 175 million from the previous year, with a year-on-year growth of 142.80% to 185.11% [3] - The previous year's net profit attributable to the parent company was CNY 124.99 million, with a net profit excluding non-recurring gains and losses of CNY 94.54 million [4] Group 2 - The substantial growth in net profit is attributed to the gradual release of growth potential from various product lines following their inclusion in centralized procurement, as well as the company's ongoing international development strategy and improved operational management [6] - The company has communicated with its auditing firm regarding the performance forecast, and there are no significant discrepancies between the company and the auditors concerning the forecast [3]

证券代码：688212 证券简称：澳华内镜 公告编号：2026-003 上海澳华内镜股份有限公司2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经上海澳华内镜股份有限公司（以下简称"公司"）财务部门初步测算： 1、预计2025年度实现营业收入为76,431万元到77,439万元，与上年同期相比，将增加1,476.05万元到 2,484.05万元，同比上升1.97%到3.31%； 2、预计2025年度实现归属于母公司所有者的净利润为805万元到1,158万元，与上年同期相比，将减少 943.22万元到1,296.22万元，同比下降44.89%到61.69%； 3、本报告期，预计2025年度归属于母公司所有者的扣除非经常性损益后的净利润为-1,053万元到-700万 元。 （三）本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况和财务状况 2024年度公司实现营业收入74,954. ...

Group 1 - The core viewpoint is that Chuangguang Medical (920300) is expected to report a net loss of between 53 million to 66 million yuan for the year 2025, indicating a narrowing of losses compared to the previous year [1][3]. - The company's revenue decline is primarily attributed to intensified competition in the magnetic resonance imaging (MRI) equipment industry and the lack of sales for the 7.0T MRI system, which is a niche product for research purposes [1][3]. - On January 29, 2026, Chuangguang Medical's stock closed at 14.99 yuan, down 1.51%, with a turnover rate of 2.55% and a trading volume of 16,900 shares, amounting to a transaction value of 25.583 million yuan [1]. Group 2 - On January 29, 2026, the net outflow of main funds was 1.2801 million yuan, accounting for 5.0% of the total transaction value [1][3]. - The net outflow of retail funds was 0.2133 million yuan, representing 0.83% of the total transaction value [1]. - The overall performance forecast indicates that the company is facing challenges in maintaining revenue levels due to market conditions [1][3].

Core Viewpoint - Wuzhou Medical (301234) is expected to report a significant decline in net profit for the year 2025, with projections indicating a drop of 47.46% to 59.97% compared to the previous year [1][3] Trading Information Summary - On January 29, 2026, Wuzhou Medical closed at 40.38 yuan, down 0.54%, with a turnover rate of 1.05%, a trading volume of 7,143 lots, and a transaction amount of 28.97 million yuan [1] - On the same day, the net inflow of funds from major investors was 1.23 million yuan, while retail investors experienced a net outflow of 4.01 million yuan [1][3] Performance Disclosure Highlights - Wuzhou Medical has released a performance forecast for 2025, estimating a net profit attributable to shareholders of 16 million to 21 million yuan, which represents a year-on-year decline of 47.46% to 59.97% [1][3] - The company also anticipates a net profit of 11 million to 16 million yuan after deducting non-recurring gains and losses, reflecting a decrease of 54.98% to 69.05% year-on-year [1] - The decline in performance is attributed to reduced operating income, falling product prices, and increased exchange losses due to currency fluctuations [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Chunli Medical (01858.HK) by 385,200 shares on January 29, with a total net reduction of 241,000 shares over the last five trading days and 3,009,300 shares over the last twenty trading days [1] - As of now, southbound funds hold 42,105,600 shares of Chunli Medical, accounting for 44.25% of the company's total issued ordinary shares [1] - Chunli Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, with key products including joint prosthetics, spinal implants, trauma products, sports medicine products, PRP products, oral products, and surgical robots [1] Group 2 - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [1]

截至2026年1月29日收盘，春立医疗(688236)报收于25.25元，上涨0.12%，换手率0.86%，成交量2.48万 手，成交额6374.46万元。 当日关注点 交易信息汇总 资金流向 1月29日主力资金净流出205.13万元，占总成交额3.22%；游资资金净流入135.14万元，占总成交额 2.12%；散户资金净流入69.99万元，占总成交额1.1%。 业绩披露要点 业绩预告 春立医疗发布业绩预告，预计2025年全年归属净利润盈利2.45亿元至2.88亿元。春立医疗发布业绩预 告，预计2025年全年扣非后净利润盈利2.3亿元至2.7亿元。 公司公告汇总 2025年年度业绩预增公告 经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润为24,498.80万元至28,798.80万 元，同比上升96.01%至130.41%；扣除非经常性损益的净利润为22,953.60万元至26,953.60万元，同比上 升142.80%至185.11%。本期业绩增长主要因产品线纳入集采后释放增长潜力，推进国际化业务布局， 提升经营管理水平和经营效率。本次业绩预告未经注册会计师审计。 以上内容为证券之星据 ...

截至2026年1月29日收盘，港通医疗(301515)报收于23.8元，下跌1.29%，换手率4.16%，成交量2.73万 手，成交额6581.84万元。 当日关注点 交易信息汇总 资金流向 1月29日主力资金净流出707.58万元；游资资金净流入295.5万元；散户资金净流入412.08万元。 四川港通医疗设备集团股份有限公司预计2025年度归属于上市公司股东的净利润亏损200.00万元至 400.00万元，上年同期为盈利1,442.19万元。扣除非经常性损益后的净利润亏损600.00万元至1,000.00万 元，上年同期盈利500.84万元。业绩变动主要原因包括合同执行进度不及预期导致营业收入下降，应收 账款增加致减值准备计提上升，理财收益下降及新投资子公司费用增加导致期间费用上升。公司已与会 计师事务所就业绩预告进行预沟通，无分歧。最终数据以2025年年度报告为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月29日主力资金净流出707.58万元，散户资金净流入412.08万元。 来自业绩披露要点：港 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of This Application Proof is in draft form. The information contained in it is incomplete and is subject to change whi ...